[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-339293-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-339293-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","superiority-of-18-f-fapi-42-petct-in-the-detection-of-primary-tumor-and-management-of-appendiceal-neoplasm-to-18-f-fdg-petct-and-ce-ct","Superiority of 18 F-FAPI-42 PET/CT in the Detection of Primary Tumor and Management of Appendiceal Neoplasm to 18 F-FDG PET/CT and CE-CT","","The study evaluates 18F-fibroblast-activation protein inhibitor (FAPI) PET/CT (18F-FAPI-42) for preoperative assessment of appendiceal neoplasms and for guiding patient management. A single-center retrospective cohort (16 untreated, 6 treated; Jan 2022–May 2023) compares 18F-FAPI-42 PET/CT with 18F-FDG PET/CT and contrast-enhanced CT, using histopathology and imaging follow-up as reference. Results show higher primary tumor and peritoneal metastasis detection and improved PCI, with treatment plan changes in a subset of patients.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/superiority-of-18-f-fapi-42-petct-in-the-detection-of-primary-tumor-and-management-of-appendiceal-neoplasm-to-18-f-fdg-petct-and-ce-ct/339293/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/superiority-of-18-f-fapi-42-petct-in-the-detection-of-primary-tumor-and-management-of-appendiceal-neoplasm-to-18-f-fdg-petct-and-ce-ct/339293.png","ImageObject",300,407,{"name":42,"@type":43},"Aurora","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What clinical value does 18F-FAPI-42 PET/CT aim to provide for appendiceal neoplasms?","Question",{"text":63,"@type":64},"It is assessed for improving preoperative evaluation of appendiceal neoplasms and for supporting management decisions in comparison with 18F-FDG PET/CT and contrast-enhanced CT.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does 18F-FAPI-42 PET/CT compare with CE-CT and 18F-FDG PET/CT in detecting primary tumors and peritoneal metastases?",{"text":68,"@type":64},"18F-FAPI-42 PET/CT shows higher accurate detection rates for primary tumors and peritoneal metastases than CE-CT and 18F-FDG PET/CT, with improved overall performance reported in the results.",{"name":70,"@type":61,"acceptedAnswer":71},"Does 18F-FAPI-42 PET/CT change treatment plans for all patients with recurrent tumors?",{"text":72,"@type":64},"Treatment plan changes were reported compared with CE-CT and 18F-FDG PET/CT, but the study indicates that management of patients with recurrent tumors was not improved by 18F-FAPI-42 PET/CT.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},339293,1790491567,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":55,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},4810365810221,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Dong et al. Cancer Imaging (2024) 24:58 [https://doi.org/10.1186/s40644-024-00706-7](https://doi.org/10.1186/s40644-024-00706-7)  \nCancer Imaging  \nRESEARCH ARTICLE Open Access  \nSuperiority of 18 F-FAPI-42 PET/CT in the  detection of primary tumor and management of appendiceal neoplasm to 18 F-FDG PET/CT and CE-CT  \nYe Dong 1,2†, Shun Huang3†, Hubing Wu 1,2†, Min Cao 1,2, Yanchao Huang 1,2, Ganghua Tang 1,2* and Wenlan Zhou 1,2*  \nAbstract  \nBackground In the present study, we investigated the value of 18 F-fibroblast-activation protein inhibitor (FAPI) positron emission tomography/computed tomography ( 18 F-FAPI-42 PET/CT) to preoperative evaluations of appendiceal neoplasms and management for patients.  \nMethods This single-center retrospective clinical study, including 16 untreated and 6 treated patients, was performed from January 2022 to May 2023 at Southern Medical University Nanfang Hospital. Histopathologic examination and imaging follow-up served as the reference standard. 18 F-FAPI-42 PET/CT was compared to 18 F-fluorodeoxyglucose ( 18 F-FDG) PET/CT and contrast-enhanced CT (CE-CT) in terms of maximal standardized uptake value (SUVmax), diagnostic efficacy and impact on treatment decisions.  \nResults The accurate detection of primary tumors and peritoneal metastases were improved from 28. 6%(4/14) and 50%(8/16) for CE-CT, and 43 . 8%(7/16) and 85 . 0%(17/20) for 18 F-FDG PET/CT, to 87 . 5%(14/16) and 100%(20/20) for 18 F-FAPI-42 PET/CT. Compared to 18 F-FDG PET/CT, 18 F-FAPI-42 PET/CT detected more regions infiltrated by peritoneal metastases (108 vs. 43), thus produced a higher peritoneal cancer index (PCI) score (median PCI: 12 vs. 5, P \u003C 0. 01) . 18 F-FAPI-42 PET/CT changed the intended treatment plans in 35. 7%(5/14) of patients compared to CE-CT and 25%(4/16) of patients compared to 18 F-FDG PET/CT but did not improve the management of patients with recurrent tumors.  \nConclusions The present study revealed that 18 F-FAPI-42 PET/CT can supplement CE-CT and 18 F-FDG PET/CT to provide a more accurate detection of appendiceal neoplasms and improved treatment decision making for patients. Keywords Appendiceal neoplasm, 18 F-FAPI-42, Contrast-enhanced CT, 18 F-FDG, PET/CT  \n†Ye Dong, Shun Huang and Hubing Wu contributed equally to this work.  \n*Correspondence: Ganghua Tang [gtang0224@smu.edu.cn](gtang0224@smu.edu.cn)[ ](gtang0224@smu.edu.cn)Wenlan Zhou [wenlanzhou@163.com](wenlanzhou@163.com)  \n1NanFang PET Center, NanFang Hospital, Southern Medical University, Guangzhou, Guangdong Province 510515, China  \n2GDMPA Key Laboratory for Quality Control and Evaluation of Radiopharmaceuticals, Department of Nuclear Medicine, Nanfang Hospital, Southern Medical University, Guangzhou,  \nGuangdong Province 510515, China  \n3Department of Nuclear Medicine, PET Center, The Tenth Affiliated Hospital of Southern Medical University (Dongguan People’s Hospital), Dongguan 523059, P. R. China  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/l](http://creativecommons.org/l)icenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ([http://creativecommons.org/publicdomain/zero/1.0/](http://creativecommons.org/publicdomain/zero/1.0/)","cbCaisumW3LFFY8p","https://ap.wps.com/l/cbCaisumW3LFFY8p","pdf",2473207,"English","# Background\n## Imaging challenges in appendiceal neoplasms\n# Methods\n## Study design and comparisons\n# Results\n## Detection performance and PCI impact\n## Treatment decision changes\n# Conclusions","[{\"question\":\"What clinical value does 18F-FAPI-42 PET/CT aim to provide for appendiceal neoplasms?\",\"answer\":\"It is assessed for improving preoperative evaluation of appendiceal neoplasms and for supporting management decisions in comparison with 18F-FDG PET/CT and contrast-enhanced CT.\"},{\"question\":\"How does 18F-FAPI-42 PET/CT compare with CE-CT and 18F-FDG PET/CT in detecting primary tumors and peritoneal metastases?\",\"answer\":\"18F-FAPI-42 PET/CT shows higher accurate detection rates for primary tumors and peritoneal metastases than CE-CT and 18F-FDG PET/CT, with improved overall performance reported in the results.\"},{\"question\":\"Does 18F-FAPI-42 PET/CT change treatment plans for all patients with recurrent tumors?\",\"answer\":\"Treatment plan changes were reported compared with CE-CT and 18F-FDG PET/CT, but the study indicates that management of patients with recurrent tumors was not improved by 18F-FAPI-42 PET/CT.\"}]","Superiority of 18 F-FAPI-42 PET/CT in the Detection of Primary Tumor and Management of Appendiceal Neoplasm to 18 F-FDG PET/CT and CE-CT | PDF",1790029301,25,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/14d4e2f59dfd1b4a3a7fdd8bd278eb81.webp",983,1310,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/eb65b9ef09ad28138448a130b31f563e.webp",982,1309,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9eef12d6a239d01191807adfcd734107.webp",981,1308,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/617b11bf25a4d950af7972141f75804d.webp",980,1306]